Abstract:Schistosomiasis, also known as bilharzia or snail fever, is a tropical parasitic disease resulting from flatworms of the Schistosoma genus. This often overlooked disease has significant impacts in affected regions, causing enduring morbidity, hindering child development, reducing productivity, and creating economic burdens. Praziquantel (PZQ) is currently the only treatment option for schistosomiasis. Given the potential rise of drug resistance and the limited treatment choices available, there is a need to develop more effective inhibitors for this neglected tropical disease (NTD). In view of this, quantitative structure-activity relationship studies (QSAR), molecular docking, molecular dynamics simulations, drug-likeness, and ADMET predictions were applied to 31 inhibitors of Schistosoma mansoni Dihydroorotate dehydrogenase (SmDHODH). The designed QSAR model demonstrated robust statistical parameters including an R 2 of 0.911, R 2 adj of 0.890, Q 2 cv of 0.686, R 2 pred of 0.807, and cR 2 p of 0.825, confirming its robustness. Compound 26 , identified as the most active derivative, emerged as a lead candidate for new potential inhibitors through ligand-based drug design. Subsequently, 12 novel compounds ( 26A - 26L ) were designed with enhanced inhibition activity and binding affinity. Molecular docking studies revealed strong and stable interactions, including hydrogen bonding and hydrophobic interactions, between the designed compounds and the target receptor. Molecular dynamics simulations over 100 nanoseconds and MM-PBSA free binding energy (ΔG bind ) calculations validated the stability of the two best-designed molecules ( 26A and 26L ). Furthermore, drug-likeness and ADMET prediction analyses affirmed the potential of these designed compounds, suggesting their promise as innovative agents for treating schistosomiasis. In an innovative effort to combat schistosomiasis, we have employed a computational drug innovation approach to design a potential treatment options. Schistosomiasis, a parasitic disease affecting millions worldwide, has been a persistent global health challenge. The study, nestled within the broader realm of life sciences, sought to identify a more effective drug using computational methods that analyze highly effective derivatives targeting SmDHODH. This pioneering approach not only accelerates the drug discovery process but also offers a promising avenue for developing targeted treatments. By harnessing computational power, we systematically explored chemical databases to pinpoint compounds with the potential to combat schistosomiasis. The findings hold significant implications for both scientists and non-scientists, as they represent a step forward in addressing a major public health concern. For scientists, this work exemplifies the integration of in silico techniques in drug development, while non-scientists can appreciate the tangible impact on improving global health and the well-being of communities affected by schistosomiasis. This research underscores the power of interdisciplinary efforts in advancing our ability to tackle complex health challenges.

Identification of Inhibitors of the Schistosoma mansoni VKR2 Kinase Domain

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

Large-scale RNAi Screening Uncovers Therapeutic Targets in the Parasite Schistosoma Mansoni.

Integration and use of Schistosoma mansoni genomic data towards the identification of candidate therapeutic targets

To Target or Not to Target Schistosoma mansoni Cyclic Nucleotide Phosphodiesterase 4A?

Protein Kinases: Potential Drug Targets Against Schistosoma japonicum

High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni

A reanalysis and integration of transcriptomics and proteomics datasets unveil novel drug targets for Mekong schistosomiasis

Crystallographic approach to fragment-based hit discovery against Schistosoma mansoni purine nucleoside phosphorylase

Aldose Reductase from Schistosoma Japonicum: Crystallization and Structure-Based Inhibitor Screening for Discovering Antischistosomal Lead Compounds.

Identification of potential inhibitors of casein kinase 2 alpha of Plasmodium falciparum with potent in vitro activity

Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S . mansoni larval and adult worm stages

Identification of potent and selective N-myristoyltransferase inhibitors of Plasmodium vivax liver stage hypnozoites and schizonts

3-oxoacyl-ACP reductase from Schistosoma japonicum: integrated in silico-in vitro strategy for discovering antischistosomal lead compounds.

Development of subunit selective proteasome substrates for

A Machine Learning Strategy for Drug Discovery Identifies Anti-Schistosomal Small Molecules

The anthelmintic meclonazepam activates a schistosome transient receptor potential channel

Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni

Identification, Characterization and Molecular Modelling Studies of Schistosoma mansoni Dihydrofolate Reductase Inhibitors: From Assay Development to Hit Identification

Venus Kinase Receptors: Prospects in Signaling and Biological Functions of These Invertebrate Kinases

Computer-aided discovery of novel SmDHODH inhibitors for schistosomiasis therapy: Ligand-based drug design, molecular docking, molecular dynamic simulations, drug-likeness, and ADMET studies